High-density lipoproteins, Part 1. Epidemiology, antiatherogenic effects, and therapies designed to increase their serum levels
Historically high-density lipoproteins (HDL) have been viewed as antiatherogenic and beneficial. This conclusion was based on early prospective longitudinal cohorts and the broad functionality of these lipoproteins which include reverse cholesterol transport as well as activities that antagonize oxi...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-09-01
|
| Series: | American Journal of Preventive Cardiology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666667725001436 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839608971222056960 |
|---|---|
| author | Beata Franczyk Ewelina Młynarska Magdalena Rysz-Górzyńska Anna Gluba-Sagr Jacek Rysz Sohum Sheth Stanislaw Surma Maciej Banach Peter P. Toth |
| author_facet | Beata Franczyk Ewelina Młynarska Magdalena Rysz-Górzyńska Anna Gluba-Sagr Jacek Rysz Sohum Sheth Stanislaw Surma Maciej Banach Peter P. Toth |
| author_sort | Beata Franczyk |
| collection | DOAJ |
| description | Historically high-density lipoproteins (HDL) have been viewed as antiatherogenic and beneficial. This conclusion was based on early prospective longitudinal cohorts and the broad functionality of these lipoproteins which include reverse cholesterol transport as well as activities that antagonize oxidation, inflammation, thrombosis, and endothelial dysfunction. It is also a key participant in immunity, engages in glucose homeostasis, and is a critical vehicle for microRNA translocation between tissues. The HDLs are polymolecular assemblies of enormous complexity. These lipoprotein particles are highly responsive in terms of cargo specificity to the interior milieu. In response to a broad range of supportive evidence, therapies have been developed that increase either serum levels of HDL particles or the mass of cholesterol in circulating HDL. Therapies that raised serum HDL-C using such agents as nicotinic acid, fibrates, or cholesterol ester transfer protein inhibitors were unsuccessful at impacting residual cardiovascular risk over and above baseline statin therapy. Although an early trial with apo-AIMilano fueled initial enthusiasm, a subsequent trial with a recombinant form of this agent was unable to reproduce its capacity to induce plaque regression as measured by IVUS. Infusible HDL mimetics have also been largely unsuccessful in reducing non-calcified plaque volume, myocardial infarct size, or cardiovascular events. More trials of longer duration and in greater numbers of patients need to be performed. Recent epidemiological studies indicate that the relationship between HDL-C and risk for cardiovascular morbidity and mortality is more complex than previously thought. Depending upon the cohort and the intensity of adjustment for risk factor covariates, the relationship is no longer viewed as inverse linear; rather, it is more U-shaped (with some exceptions) with high and low levels of HDL-C both being associated with heightened risk for events. The issue clearly requires much greater investigation. Given the enormous complexity of the HDL proteome and lipidome and the range of functions it has the capacity to participate in, the potential to harness beneficial effects from HDL remain a viable possibility. However, the HDL code is yet to be fully deciphered. A polymolecular assembly as complex as mature HDL is not a simple task to study. Risk algorithms need to reassess the validity of attributing cardioprotection from high HDL-C as this may lead to underestimation of true risk. |
| format | Article |
| id | doaj-art-dba8a5ec6ad54d2280a5ab6d767a223d |
| institution | Matheson Library |
| issn | 2666-6677 |
| language | English |
| publishDate | 2025-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | American Journal of Preventive Cardiology |
| spelling | doaj-art-dba8a5ec6ad54d2280a5ab6d767a223d2025-07-31T04:53:58ZengElsevierAmerican Journal of Preventive Cardiology2666-66772025-09-0123101068High-density lipoproteins, Part 1. Epidemiology, antiatherogenic effects, and therapies designed to increase their serum levelsBeata Franczyk0Ewelina Młynarska1Magdalena Rysz-Górzyńska2Anna Gluba-Sagr3Jacek Rysz4Sohum Sheth5Stanislaw Surma6Maciej Banach7Peter P. Toth8Department of Nephrology, Hypertension and Family Medicine, Medical University of Lodz, 113 Żeromskiego Street, Lodz 90-549, PolandDepartment of Nephrology, Hypertension and Family Medicine, Medical University of Lodz, 113 Żeromskiego Street, Lodz 90-549, PolandDepartment of Ophthalmology and Visual Rehabilitation, Medical University of Lodz, Lodz 90-549, PolandDepartment of Nephrology, Hypertension and Family Medicine, Medical University of Lodz, 113 Żeromskiego Street, Lodz 90-549, PolandDepartment of Nephrology, Hypertension and Family Medicine, Medical University of Lodz, 113 Żeromskiego Street, Lodz 90-549, PolandUniversity of Florida College of Medicine, Gainesville, FL, USADepartment of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Medyków 18, Katowice 40-752, Poland; Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Rzgowska 281/289, Lodz 93-228, PolandDepartment of Preventive Cardiology and Lipidology, Medical University of Lodz, Lodz 93-338, Poland; Faculty of Medicine, The John Paul II Catholic University of Lublin, Al. Racławickie 14, Lublin 20-950, Poland; Cicarrone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, USACGH Medical Center, 101 East Miller Rd, Sterling, IL, USA; Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Corresponding author at: CGH Medical Center, 101 East Miller Rd, Sterling, IL, USA.Historically high-density lipoproteins (HDL) have been viewed as antiatherogenic and beneficial. This conclusion was based on early prospective longitudinal cohorts and the broad functionality of these lipoproteins which include reverse cholesterol transport as well as activities that antagonize oxidation, inflammation, thrombosis, and endothelial dysfunction. It is also a key participant in immunity, engages in glucose homeostasis, and is a critical vehicle for microRNA translocation between tissues. The HDLs are polymolecular assemblies of enormous complexity. These lipoprotein particles are highly responsive in terms of cargo specificity to the interior milieu. In response to a broad range of supportive evidence, therapies have been developed that increase either serum levels of HDL particles or the mass of cholesterol in circulating HDL. Therapies that raised serum HDL-C using such agents as nicotinic acid, fibrates, or cholesterol ester transfer protein inhibitors were unsuccessful at impacting residual cardiovascular risk over and above baseline statin therapy. Although an early trial with apo-AIMilano fueled initial enthusiasm, a subsequent trial with a recombinant form of this agent was unable to reproduce its capacity to induce plaque regression as measured by IVUS. Infusible HDL mimetics have also been largely unsuccessful in reducing non-calcified plaque volume, myocardial infarct size, or cardiovascular events. More trials of longer duration and in greater numbers of patients need to be performed. Recent epidemiological studies indicate that the relationship between HDL-C and risk for cardiovascular morbidity and mortality is more complex than previously thought. Depending upon the cohort and the intensity of adjustment for risk factor covariates, the relationship is no longer viewed as inverse linear; rather, it is more U-shaped (with some exceptions) with high and low levels of HDL-C both being associated with heightened risk for events. The issue clearly requires much greater investigation. Given the enormous complexity of the HDL proteome and lipidome and the range of functions it has the capacity to participate in, the potential to harness beneficial effects from HDL remain a viable possibility. However, the HDL code is yet to be fully deciphered. A polymolecular assembly as complex as mature HDL is not a simple task to study. Risk algorithms need to reassess the validity of attributing cardioprotection from high HDL-C as this may lead to underestimation of true risk.http://www.sciencedirect.com/science/article/pii/S2666667725001436AtherosclerosisEpidemiologyHigh-density lipoproteinInflammationOxidationReverse cholesterol transport |
| spellingShingle | Beata Franczyk Ewelina Młynarska Magdalena Rysz-Górzyńska Anna Gluba-Sagr Jacek Rysz Sohum Sheth Stanislaw Surma Maciej Banach Peter P. Toth High-density lipoproteins, Part 1. Epidemiology, antiatherogenic effects, and therapies designed to increase their serum levels American Journal of Preventive Cardiology Atherosclerosis Epidemiology High-density lipoprotein Inflammation Oxidation Reverse cholesterol transport |
| title | High-density lipoproteins, Part 1. Epidemiology, antiatherogenic effects, and therapies designed to increase their serum levels |
| title_full | High-density lipoproteins, Part 1. Epidemiology, antiatherogenic effects, and therapies designed to increase their serum levels |
| title_fullStr | High-density lipoproteins, Part 1. Epidemiology, antiatherogenic effects, and therapies designed to increase their serum levels |
| title_full_unstemmed | High-density lipoproteins, Part 1. Epidemiology, antiatherogenic effects, and therapies designed to increase their serum levels |
| title_short | High-density lipoproteins, Part 1. Epidemiology, antiatherogenic effects, and therapies designed to increase their serum levels |
| title_sort | high density lipoproteins part 1 epidemiology antiatherogenic effects and therapies designed to increase their serum levels |
| topic | Atherosclerosis Epidemiology High-density lipoprotein Inflammation Oxidation Reverse cholesterol transport |
| url | http://www.sciencedirect.com/science/article/pii/S2666667725001436 |
| work_keys_str_mv | AT beatafranczyk highdensitylipoproteinspart1epidemiologyantiatherogeniceffectsandtherapiesdesignedtoincreasetheirserumlevels AT ewelinamłynarska highdensitylipoproteinspart1epidemiologyantiatherogeniceffectsandtherapiesdesignedtoincreasetheirserumlevels AT magdalenaryszgorzynska highdensitylipoproteinspart1epidemiologyantiatherogeniceffectsandtherapiesdesignedtoincreasetheirserumlevels AT annaglubasagr highdensitylipoproteinspart1epidemiologyantiatherogeniceffectsandtherapiesdesignedtoincreasetheirserumlevels AT jacekrysz highdensitylipoproteinspart1epidemiologyantiatherogeniceffectsandtherapiesdesignedtoincreasetheirserumlevels AT sohumsheth highdensitylipoproteinspart1epidemiologyantiatherogeniceffectsandtherapiesdesignedtoincreasetheirserumlevels AT stanislawsurma highdensitylipoproteinspart1epidemiologyantiatherogeniceffectsandtherapiesdesignedtoincreasetheirserumlevels AT maciejbanach highdensitylipoproteinspart1epidemiologyantiatherogeniceffectsandtherapiesdesignedtoincreasetheirserumlevels AT peterptoth highdensitylipoproteinspart1epidemiologyantiatherogeniceffectsandtherapiesdesignedtoincreasetheirserumlevels |